Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 14/20 | 0.47 |
| ▸ | CA2 | P00918 | 14/20 | 0.47 |
| ▸ | CA4 | P22748 | 5/20 | 0.47 |
| ▸ | CA7 | P43166 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA6 | P23280 | 5/20 | 0.46 |
| ▸ | CA5A | P35218 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.46 |
| ▸ | CA3 | P07451 | 4/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9041431 | 0.84 | CDC25B (0.46) | CDC25BCYP1A2PKMCYP3A4LMNA | |
| SCHEMBL9042101 | 0.84 | CA1 (0.56) | CA1CA2CA4CA7CA12 | |
| SCHEMBL11756625 | 0.82 | CA1 (0.47) | CDC25BCA1CA2CA4CA7 | |
| SCHEMBL11794834 | 0.81 | CDC25B (0.50) | CDC25BCA1CA2CA4CA7 | |
| SCHEMBL1931732 | 0.80 | TPMT (0.54) | CDC25BCA1CA2CA4CA7 | |
| SCHEMBL11543864 | 0.80 | ALDH1A1 (0.46) | CA1CA2CA4CA7CA12 | |
| SCHEMBL573694 | 0.80 | PKM (0.44) | CA1CA2CA4CA7CA12 | |
| SCHEMBL10281394 | 0.79 | CDC25B (0.47) | CDC25BCA1CA2CA4CA7 | |
| SCHEMBL13283935 | 0.79 | PKM (0.49) | CDC25BCA1CA2CA4CA7 | |
| SCHEMBL12831123 | 0.78 | NEU3 (0.48) | CDC25BCA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| US-4176190-A | Diuretic and saliuretic sulphamoylbenzoic acids | CIBA-GEIGY CORPORATION (US) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CDC25B 4865/4885CA1 1022/4885CA2 471/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CDC25B 4860/4885CA1 701/4885CA2 388/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CDC25B 3365/4885CA1 1755/4885CA2 1572/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CDC25B 3893/4885CA1 1762/4885CA2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.